3.81
2.31%
-0.09
After Hours:
3.83
0.02
+0.52%
Geron Corp. stock is currently priced at $3.81, with a 24-hour trading volume of 6.88M.
It has seen a -2.31% decreased in the last 24 hours and a +3.53% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.88 pivot point. If it approaches the $3.77 support level, significant changes may occur.
Previous Close:
$3.90
Open:
$3.91
24h Volume:
6.88M
Market Cap:
$2.26B
Revenue:
$237.00K
Net Income/Loss:
$-184.13M
P/E Ratio:
-11.21
EPS:
-0.34
Net Cash Flow:
$-168.57M
1W Performance:
+0.26%
1M Performance:
+3.53%
6M Performance:
+93.40%
1Y Performance:
+26.16%
Geron Corp. Stock (GERN) Company Profile
Name
Geron Corp.
Sector
Industry
Phone
650-473-7700
Address
149 Commonwealth Drive, Suite 2070, Menlo Park, CA
Geron Corp. Stock (GERN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
Mar-28-23 | Initiated | Goldman | Neutral |
Oct-28-22 | Initiated | Wedbush | Outperform |
Jul-28-22 | Resumed | B. Riley Securities | Buy |
Nov-02-21 | Initiated | Robert W. Baird | Outperform |
Feb-18-21 | Resumed | B. Riley Securities | Buy |
Aug-03-20 | Initiated | Stifel | Buy |
Nov-19-19 | Resumed | B. Riley FBR | Buy |
Sep-03-19 | Initiated | H.C. Wainwright | Buy |
Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
Apr-09-19 | Upgrade | Needham | Hold → Buy |
Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
Sep-13-16 | Reiterated | FBR & Co. | Outperform |
Sep-13-16 | Reiterated | FBR Capital | Outperform |
Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
Apr-21-15 | Initiated | Oppenheimer | Outperform |
Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
Dec-10-13 | Reiterated | MLV & Co | Buy |
Dec-10-13 | Upgrade | Needham | Hold → Buy |
Nov-08-13 | Reiterated | MLV & Co | Buy |
Oct-16-13 | Initiated | MLV & Co | Buy |
Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp. Stock (GERN) Latest News
Geron Corp's blood cancer drug succeeds in late-stage study - Yahoo Sport Australia
Yahoo Sport Australia
Geron (NASDAQ:GERN) Shares Down 3.6% - MarketBeat
MarketBeat
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Business Wire
New York State Common Retirement Fund Boosts Stake in Geron Co. (NASDAQ:GERN) - Defense World
Defense World
Russell Investments Group Ltd. Buys 204765 Shares of Geron Co. (NASDAQ:GERN) - Defense World
Defense World
Geron Co. (NASDAQ:GERN) is Vivo Capital LLC's 7th Largest Position - MarketBeat
MarketBeat
Geron Corp. Stock (GERN) Financials Data
Geron Corp. (GERN) Revenue 2024
GERN reported a revenue (TTM) of $237.00 thousand for the quarter ending December 31, 2023, a -60.23% decline year-over-year.
Geron Corp. (GERN) Net Income 2024
GERN net income (TTM) was -$184.13 million for the quarter ending December 31, 2023, a -29.76% decrease year-over-year.
Geron Corp. (GERN) Cash Flow 2024
GERN recorded a free cash flow (TTM) of -$168.57 million for the quarter ending December 31, 2023, a -31.89% decrease year-over-year.
Geron Corp. (GERN) Earnings per Share 2024
GERN earnings per share (TTM) was -$0.33 for the quarter ending December 31, 2023, a +8.33% growth year-over-year.
About Geron Corp.
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Cap:
|
Volume (24h):